| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 06/08/2006 | US20060121025 VEGF-related protein |
| 06/08/2006 | US20060121022 an antibody against protein C or activated protein C (aPC) comprising the heavy chain and light chain complementarity determining regions; used for suppressing activation of the blood coagulation system and antiinflammatory activity; therapy for diseases such as thrombosis and sepsis |
| 06/08/2006 | US20060121021 by which blood cells can be stimulated; amount of required mAbs is lower than when using the same mAbs in a solution, which makes the stimulation independent from the presence or the quality of non-T cells carrying Fc-receptors, and which can be prepared in an easier way under GMP conditions |
| 06/08/2006 | US20060120959 Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| 06/08/2006 | US20060120956 Imaging agents comprising barbituric acid derivatives |
| 06/08/2006 | DE10256042B4 Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren A method of selecting cells that produce specific binding molecules |
| 06/08/2006 | DE10081928B4 6-O-Acetylmorphin (6MAM)-Analoge Verbindungen, welche zur Verwendung in Immuntests geeignet sind, hiergegen gewonnene Antikörper, deren Herstellung sowie Reagentien und Reagenssysteme, die diese umfassen 6-O-acetylmorphine (6MAM) analogs compounds which are suitable for use in immunoassays, antibody obtained against this, their preparation as well as reagents and reagent systems which comprise these |
| 06/08/2006 | CA2590583A1 Use of endosialin binding proteins to isolate endosialin positive cells |
| 06/08/2006 | CA2590419A1 Modulation of ovulation |
| 06/08/2006 | CA2589898A1 Modulation of ovulation |
| 06/08/2006 | CA2589885A1 Biomarkers for pre-selection of patients for anti-igf1r therapy |
| 06/08/2006 | CA2589839A1 Method for affinity purification |
| 06/08/2006 | CA2589802A1 Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
| 06/08/2006 | CA2589800A1 Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| 06/08/2006 | CA2589636A1 Toll like receptor 3 antagonists, methods and uses |
| 06/08/2006 | CA2588892A1 Anti-il-1r1 single domain antibodies and therapeutic uses |
| 06/08/2006 | CA2588253A1 Methods and systems for prognosis and treatment of solid tumors |
| 06/08/2006 | CA2587638A1 Anti-tenascin monoclonal antibody immunoassays and diagnostic kits |
| 06/08/2006 | CA2584137A1 Methods for refolding polypeptides |
| 06/08/2006 | CA2580801A1 Naturally occuring igm antibodies that bind lymphocytes |
| 06/08/2006 | CA2489940A1 Relay vaccine |
| 06/07/2006 | EP1666600A1 Methods for enhancing the efficacy of cancer therapy |
| 06/07/2006 | EP1666597A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666596A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666595A1 GAB2 (P97) gene and methods of use thereof |
| 06/07/2006 | EP1666594A2 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer |
| 06/07/2006 | EP1666591A1 Cytokine that induces apoptosis |
| 06/07/2006 | EP1666590A1 Lrp4/corin dopamine-producing neuron precursor cell marker |
| 06/07/2006 | EP1666501A1 Sugar chain-modified anti-hm1.24 antibody |
| 06/07/2006 | EP1666500A1 Use of trifunctionel antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy |
| 06/07/2006 | EP1666499A2 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/07/2006 | EP1666498A2 Soluble CTLA4 molecules, compositions comprising said molecules and uses thereof |
| 06/07/2006 | EP1666497A2 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer |
| 06/07/2006 | EP1666495A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666494A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666493A1 Secreted and transmembrane polypeptides and nucleic acids ancoding the same |
| 06/07/2006 | EP1666492A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666491A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666063A2 Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 06/07/2006 | EP1666062A2 Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5c8 |
| 06/07/2006 | EP1666061A1 Use of antibody |
| 06/07/2006 | EP1666052A1 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 06/07/2006 | EP1664785A1 Combination of anti-hpv-16 and 18 antibodies and uses thereof |
| 06/07/2006 | EP1664774A2 A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method |
| 06/07/2006 | EP1664769A2 Assay for detecting atrial and brain natriuretic peptide prohormones |
| 06/07/2006 | EP1664343A2 Methods and compositions for generation of germline human antibody genes |
| 06/07/2006 | EP1664322A2 Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| 06/07/2006 | EP1664321A2 Methods for expression and purification of immunotoxins |
| 06/07/2006 | EP1664312A1 Rodent expression systems utilising polyoma virus and epstein barr virus sequences |
| 06/07/2006 | EP1664304A1 Method for neutralizing effects of secreted pla2 iia |
| 06/07/2006 | EP1664289A2 Cyclic nucleotide-specific phosphodiesterases from leishmania and uses thereof |
| 06/07/2006 | EP1664272A2 Targeting endothelium for tissue-specific delivery of agents |
| 06/07/2006 | EP1664270A1 Chimeric antigens for breaking host tolerance to foreign antigens |
| 06/07/2006 | EP1664124A2 Product comprising a c4bp core protein and a monomeric antigen, and its use |
| 06/07/2006 | EP1664122A2 Therapeutic binding molecules against cd45 isoforms |
| 06/07/2006 | EP1664121A1 Antibodies against interleukin-1 receptor and uses thereof |
| 06/07/2006 | EP1664120A1 Antibody specifically binding to sulfonylated protein and method for producing the same |
| 06/07/2006 | EP1664119A1 Method for the treatment or prophylaxis of tuberculosis |
| 06/07/2006 | EP1664118A1 Tlr2 antagonistic antibody and use thereof |
| 06/07/2006 | EP1664117A2 Immunogen |
| 06/07/2006 | EP1664116A2 Improved antibodies having altered effector function and methods for making the same |
| 06/07/2006 | EP1664115A2 Antibody cdr polypeptide sequences with restricted diversity |
| 06/07/2006 | EP1664103A2 Genetic products which are differentially expressed in tumours and use thereof |
| 06/07/2006 | EP1664099A2 Adenoviral epitopes |
| 06/07/2006 | EP1664097A2 Piroplasmid vaccine |
| 06/07/2006 | EP1664085A1 Detecting molecules |
| 06/07/2006 | EP1664082A2 Kid3 and kid3 antibodies that bind thereto |
| 06/07/2006 | EP1664081A2 Novel proteins and nucleic acids encoding same |
| 06/07/2006 | EP1663320A1 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| 06/07/2006 | EP1663309A2 Methods and compositions for treating herpes infections |
| 06/07/2006 | EP1663308A1 Compositions and methods to accelerate hematologic recovery |
| 06/07/2006 | EP1663307A2 Method for treating, preventing and/or diagnosing cancer, related to the use of mal2 polypeptide |
| 06/07/2006 | EP1663306A2 Antibodies with altered effector functions |
| 06/07/2006 | EP1663305A1 A method selecting an immunotherapeutic preparation |
| 06/07/2006 | EP1663304A2 Treatment of rheumatoid arthritis with cd99 antagonists |
| 06/07/2006 | EP1663301A1 Vaccines |
| 06/07/2006 | EP1663290A2 Modulators of p-selectin glycoprotein ligand 1 |
| 06/07/2006 | EP1663288A2 Methods of using wisp antagonists |
| 06/07/2006 | EP1663259A2 Compositions and methods for treatment of cancer |
| 06/07/2006 | EP1663146A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 06/07/2006 | EP1576157A4 Fluorescent proteins from copepoda species and methods for using same |
| 06/07/2006 | EP1565564A4 Modified antibodies stably produced in milk and methods of producing same |
| 06/07/2006 | EP1517921B1 Dual specific ligands with increased serum half-life |
| 06/07/2006 | EP1476467B1 Immunoglobulin igg3 as a marker for protecting against infectious viral diseases, and the uses of the same |
| 06/07/2006 | EP1409673B1 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 06/07/2006 | EP1364023B1 Gene highly expressed in cartilage tissues |
| 06/07/2006 | EP1320552B8 Method for producing human anti-thymocyte immunoglobulins |
| 06/07/2006 | EP1309690B1 Mfq-111, a human gtpase like protein |
| 06/07/2006 | EP1104307B1 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| 06/07/2006 | EP1095059B1 Chemotaxis inhibiting protein of staphylococcus (chips) and its use |
| 06/07/2006 | EP1081224B1 Novel method for cloning a gene |
| 06/07/2006 | EP1051620B1 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha |
| 06/07/2006 | EP1038015B1 Mood disorder gene |
| 06/07/2006 | EP1002081B1 Delayed progression to aids by a missense allele of the ccr2 gene |
| 06/07/2006 | EP0972015B1 Enzyme having s-adenosyl-l-homocysteine hydrolase (ahcy) type activity |
| 06/07/2006 | EP0813538B1 Compositions and methods for the treatment and diagnosis of immune disorders |
| 06/07/2006 | EP0783583B1 Cytoplasmic tyrosine kinase |
| 06/07/2006 | CN1784426A Antibody targeted at antigen specific to cancer |
| 06/07/2006 | CN1784425A Method of detecting probnp with a monoclonal antibody binding to the amino acids 38-44 |
| 06/07/2006 | CN1784422A Severe acute respiratory syndrome (SARS) causing coronavirus |